Matches in Wikidata for { <http://www.wikidata.org/entity/Q58030165> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q58030165 description "2011 թվականի մայիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q58030165 description "article scientifique publié en 2011" @default.
- Q58030165 description "artículu científicu espublizáu en mayu de 2011" @default.
- Q58030165 description "im Mai 2011 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58030165 description "scientific article published on 11 May 2011" @default.
- Q58030165 description "wetenschappelijk artikel" @default.
- Q58030165 description "наукова стаття, опублікована в травні 2011" @default.
- Q58030165 name "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 name "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 type Item @default.
- Q58030165 label "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 label "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 prefLabel "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 prefLabel "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 P1433 Q58030165-7864AFAE-BFD3-4267-92DD-2376F4C6018A @default.
- Q58030165 P1476 Q58030165-15A7A914-685B-45CC-B94E-92455F6BC699 @default.
- Q58030165 P2093 Q58030165-0EA96EE0-C273-4ECE-A4E0-7C9939139277 @default.
- Q58030165 P2093 Q58030165-19F963FC-6D1B-4DA5-93C5-5D785D081110 @default.
- Q58030165 P2093 Q58030165-2B1B0E69-4981-4907-B3F2-5307ACFC9586 @default.
- Q58030165 P2093 Q58030165-32273EA8-B00D-49DC-A4CF-A58B07671757 @default.
- Q58030165 P2093 Q58030165-37909D4E-826F-4337-AA36-4917ED2DE28C @default.
- Q58030165 P2093 Q58030165-3947682C-18C4-4517-AD26-3EFFF8BB0FFC @default.
- Q58030165 P2093 Q58030165-3BE7B7BB-4F97-4580-B881-E99A4579E280 @default.
- Q58030165 P2093 Q58030165-591867D4-0AE4-4E4B-B06F-EB9ACCA511B3 @default.
- Q58030165 P2093 Q58030165-71A7B2CB-7CFE-45ED-BF9B-96D03D6A49C8 @default.
- Q58030165 P2093 Q58030165-8FCE38BF-55BF-441A-9F25-DA800DC00625 @default.
- Q58030165 P2093 Q58030165-C595BDE9-D34A-48FD-B552-66CD4962E235 @default.
- Q58030165 P2093 Q58030165-CF8FDEFB-9205-4001-9774-D51E67B47AB6 @default.
- Q58030165 P2093 Q58030165-E003B97E-5A6C-46E2-BE80-859FFD547214 @default.
- Q58030165 P304 Q58030165-A483F9EE-E813-4513-852C-E8BA407AB9D8 @default.
- Q58030165 P31 Q58030165-B5B853B1-957C-4BC1-AA2C-F4069AF30140 @default.
- Q58030165 P356 Q58030165-8946629F-12E4-4BF2-AD19-4D57FBDD2257 @default.
- Q58030165 P407 Q58030165-CF976C42-8A15-4EBD-9EA0-101F88869035 @default.
- Q58030165 P433 Q58030165-523E60C5-D5D3-457B-8EC9-A66035C73962 @default.
- Q58030165 P478 Q58030165-4094F8F1-2ECF-492E-A907-5B858CAA11DC @default.
- Q58030165 P50 Q58030165-39D083A3-F98E-4D04-A056-F08B3034B74D @default.
- Q58030165 P50 Q58030165-8EC63A04-094F-4BFE-8A12-D15E51725350 @default.
- Q58030165 P50 Q58030165-A885B95F-81E5-4ABC-943A-66A32816E7B8 @default.
- Q58030165 P577 Q58030165-85213938-E0EA-48ED-A314-BB1321398FDC @default.
- Q58030165 P698 Q58030165-4EA4C2D9-D458-4CA1-8DA1-66EBACC4DBFF @default.
- Q58030165 P921 Q58030165-998C00F9-0305-4162-95D0-848A465B3A79 @default.
- Q58030165 P921 Q58030165-C61836B4-0333-46B4-BCD4-A540A9FE2F26 @default.
- Q58030165 P356 BLOOD-2011-02-334227 @default.
- Q58030165 P698 21562045 @default.
- Q58030165 P1433 Q885070 @default.
- Q58030165 P1476 "Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study" @default.
- Q58030165 P2093 "Andrew Cakana" @default.
- Q58030165 P2093 "Christopher Enny" @default.
- Q58030165 P2093 "Dixie-Lee Esseltine" @default.
- Q58030165 P2093 "Donna E Reece" @default.
- Q58030165 P2093 "Hani Hassoun" @default.
- Q58030165 P2093 "Helgi van de Velde" @default.
- Q58030165 P2093 "Jean-Paul Fermand" @default.
- Q58030165 P2093 "Joan Bladé" @default.
- Q58030165 P2093 "Kevin Liu" @default.
- Q58030165 P2093 "Leonard Heffner" @default.
- Q58030165 P2093 "Raymond L Comenzo" @default.
- Q58030165 P2093 "Robert A Vescio" @default.
- Q58030165 P2093 "Ute Hegenbart" @default.
- Q58030165 P304 "865-873" @default.
- Q58030165 P31 Q13442814 @default.
- Q58030165 P356 "10.1182/BLOOD-2011-02-334227" @default.
- Q58030165 P407 Q1860 @default.
- Q58030165 P433 "4" @default.
- Q58030165 P478 "118" @default.
- Q58030165 P50 Q37839091 @default.
- Q58030165 P50 Q37839101 @default.
- Q58030165 P50 Q42787183 @default.
- Q58030165 P577 "2011-05-11T00:00:00Z" @default.
- Q58030165 P698 "21562045" @default.
- Q58030165 P921 Q181600 @default.
- Q58030165 P921 Q4652470 @default.